Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid

Abdullah, Hilmi and Mohamad Ismail, Asmahan and Rosman, Azmillah (2012) Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. Medical Journal of Malaysia, 67 (1). pp. 125-126. ISSN 0300-5283

	PDF (Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid) - Published Version Restricted to Repository staff only Download (73kB) | Request a copy
	PDF (scopus) - Supplemental Material Restricted to Repository staff only Download (450kB) | Request a copy

Abstract

Urate lowering therapy in this country has mainly been achieved by the use of allopurinol and probenecid. A new xanthine oxidase inhibitor called febuxostat has been approved in 2009 for treatment of hyperuricaemia in gout. In this report, we describe the management of a patient with chronic tophaceous gout using febuxostat. The reduction in serum uric acid to target levels was rapid, and the tophi size had also reduced significantly while on therapy. There was no unwanted side effect observed during the therapy. Therefore, febuxostat would be a useful alternative drug in the treatment of hyperuricaemia in gout patients who have contraindications to allopurinol and probenecid

Item Type:	Article (Journal)
Additional Information:	4443/29313
Uncontrolled Keywords:	febuxostat, chronic tophaceous gout, allopurinol,probenecid
Subjects:	R Medicine > R Medicine (General)
Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button):	Kulliyyah of Medicine
Depositing User:	Dr Hilmi Abdullah
Date Deposited:	01 Mar 2013 14:34
Last Modified:	28 Sep 2017 15:18
URI:	http://irep.iium.edu.my/id/eprint/29313

Actions (login required)

View Item